Development of a standardised non-medical treatment for inducible laryngeal obstruction

ISRCTN ISRCTN18291587
DOI https://doi.org/10.1186/ISRCTN18291587
IRAS number 335820
Secondary identifying numbers IRAS 335820, Sponsor reference NHS002135
Submission date
23/01/2024
Registration date
25/01/2024
Last edited
25/10/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Ear, Nose and Throat
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Inducible laryngeal obstruction (ILO) is when the larynx (voice box) inappropriately closes. This leads to breathing difficulties and individuals may seek help from primary care, emergency departments or need to be admitted to hospital. Currently there is no standard approach to treat ILO once it is diagnosed. Non-pharmacological interventions (treatment without medication) are often recommended and used in the clinical setting but is not yet known what the possible key components of non-pharmacological interventions are and whether they are acceptable to individuals with ILO. The aim of this study is to develop and describe a non-pharmacological standardised intervention for adults with ILO.

Who can participate?
1. Healthcare professionals experienced in assessing, diagnosing and delivering non-pharmacological interventions to adults with ILO (defined as holding a regular ILO caseload of >3 years)
2. Patients aged over 18 years with an established diagnosis of ILO based on clinical evaluation and endoscopic visualisation of laryngeal obstruction during a symptomatic episode.

What does the study involve?
It will be in three phases:
Stage 1: A 60-90-minute focus group with 5-7 health care professionals will be held virtually. It will explore attitudes and beliefs on the timing of ILO intervention, how much should be given, how and what should be delivered. The meeting will be transcribed and analysed for any themes.
Stage 2: One-to-one (30-45 minutes) interviews with 20-27 patients diagnosed with ILO, will explore patient opinion on interventions. An interview guide will be developed based on Stage 1. The meetings will be held virtually, transcribed, and then analysed. Following analysis, a draft of a standardised non-pharmacological intervention for adults with ILO will be prepared.
Stage 3: The draft manual will be shown to participants from Stages 1 and 2, together with a questionnaire to check for content, understanding and acceptability. Based on feedback, any required changes will be made and a final manual produced.

What are the possible benefits and risks of participating?
Taking part in the study will have no direct benefit to participants. There are no identified significant risks to taking part. The study will not explore patients' experience of living with ILO.

Where is the study run from?
University of Manchester (UK)

When is the study starting and how long is it expected to run for?
September 2023 to December 2024

Who is funding the study?
1. Manchester Biomedical Research Centre (UK)
2. North West Lung Centre Charity (UK)

Who is the main contact?
Jemma Haines, jemma.haines@mft.nhs.uk

Contact information

Mrs Jemma Haines
Public, Principal Investigator

Manchester University NHS Foundation Trust
2nd Floor Education and Research Centre
Southmoor Road
Wythenshawe
Manchester
M23 9LT
United Kingdom

ORCiD logoORCID ID 0000-0003-3813-041X
Phone +44 (0)161 2914245
Email jemma.haines@mft.nhs.uk
Prof Stephen J Fowler
Scientific

Manchester University NHS Foundation Trust
2nd Floor Education and Research Centre
Southmoor Road
Wythenshawe
Manchester
M23 9LT
United Kingdom

ORCiD logoORCID ID 0000-0002-4524-1663
Phone +44 (0)1612914245
Email stephen.fowler@manchester.ac.uk

Study information

Study designSingle-centre qualitative interview and questionnaire study
Primary study designObservational
Secondary study designQualitative study
Study setting(s)Internet/virtual
Study typeTreatment
Participant information sheet Not available in web format please use contact details to request a participant information sheet
Scientific titleInducible Laryngeal Obstruction in adults: developing a standardised non-pharmacological Intervention
Study acronymILO-i
Study objectivesCurrently there is no standard approach to treat Inducible Laryngeal Obstruction (ILO) once it is diagnosed. There are no licenced medications available and non-pharmacological interventions (treatment without medication) are often recommended in a clinical setting.

The purpose of this research is to understand what the possible key components of non-pharmacological interventions are and whether they are acceptable to individuals with ILO.
Ethics approval(s)

Approved 15/02/2024, North West Greater Manchester South (3rd Floor, Barlow House, 4 Minshull Street, HRA NRES Centre, Manchester, M1 3DZ, United Kingdom; +44 (0)20711048014; gmsouth.rec@hra.nhs.uk), ref: 24/NW/0010

Health condition(s) or problem(s) studiedInducible Laryngeal Obstruction in adults
InterventionStage 1: A 60-90 minutes focus group (with 5-7 experienced health care professionals experienced in delivering non-pharmacological interventions to adults with ILO)

Stage 2: One-to-one (30-45 minutes) interviews with 20-27 patients diagnosed with ILO

Stage 3: The draft manual will be shown to participants from Stage 1 and 2, together with a bespoke questionnaire to check for content, clarity and acceptability. Based on feedback, any required changes will be made and a final manual produced.
Intervention typeOther
Primary outcome measureParticipant opinions/responses (variable) to questions regarding non-pharmacological interventions for ILO will be measured in a focus group/interview at a single timepoint using data transcript thematic analysis
Secondary outcome measuresParticipant responses (variable) to a debriefing questionnaire on a draft standardised treatment manual for ILO will be measured at a single timepoint using thematic analysis
Overall study start date23/09/2023
Completion date31/12/2024

Eligibility

Participant type(s)Patient, Health professional
Age groupMixed
Lower age limit18 Years
Upper age limit99 Years
SexBoth
Target number of participantsTotal target recruitment of participants: 34 (healthcare professionals: 5-7; treatment naïve patient participants 5-7; patients post treatment 15-20).
Key inclusion criteriaHealthcare professionals:
1. Experienced (defined as holding a regular ILO caseload for >3 years) in assessing, diagnosing and delivering nonpharmacological treatment to adults with ILO

Treatment naïve patients:
1. An established diagnosis of ILO based on i) clinical evaluation AND ii) endoscopic visualisation of laryngeal obstruction during a symptomatic episode
2. >18 years old
3. Have not received and completed non-pharmacological / behavioural therapy intervention for ILO

Post-treatment patients:
1. An established diagnosis of ILO based on i) clinical evaluation and ii) endoscopic visualisation of laryngeal obstruction during a symptomatic episode
2. >18 years old
3. Have received and completed a non-pharmacological behavioural therapy intervention for ILO
Key exclusion criteriaHealthcare professionals:
1. Healthcare professionals who have no specialist experience in assessing, diagnosing and delivering nonpharmacological treatment to adults with ILO

Treatment naïve patients:
1. Have received any previous therapy intervention for ILO, refractory chronic cough or upper airway symptoms (e.g.
muscle tension dysphonia, globus pharyngeaous)
2. Have uncontrolled asthma airway inflammation or obstruction (defined as fractional exhaled nitric oxide >50ppb,
FEV1/FVC <70%)

Post-treatment patients:
1. Have completed a non-pharmacological behavioural therapy intervention for ILO greater than 4 months prior to study
2. Have uncontrolled airway inflammation or obstruction (defined as fractional exhaled nitric oxide >50ppb, FEV1/FVC
<70%)
Date of first enrolment01/03/2024
Date of final enrolment31/12/2024

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centres

Manchester University NHS Foundation Trust
Wythenshawe Hospital
Southmoor Road
Wythenshawe
Manchester
M23 9LT
United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital
Herries Road
Sheffield
S5 7AU
United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
B15 2GW
United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Royal Preston Hospital
Sharoe Green Lane
Fulwood
Preston
PR2 9HT
United Kingdom

Sponsor information

University of Manchester
University/education

Faculty of Biology, Medicine and Health
5.012 Carys Bannister Building
Manchester
M13 9PL
England
United Kingdom

Phone +44 (0)161 2755318
Email FBMHethics@manchester.ac.uk
Website http://www.manchester.ac.uk/
ROR logo "ROR" https://ror.org/027m9bs27

Funders

Funder type

Government

Manchester Biomedical Research Centre
Government organisation / Research institutes and centers
Alternative name(s)
NIHR Manchester Biomedical Research Centre, Manchester BRC, NIHR Manchester BRC, NIHR Manchester Biomedical Research Unit, Manchester NIHR BRC, Manchester NIHR Biomedical Research Centre, Biomedical Research Centre, BRC, NIHR BRC
Location
United Kingdom
North West Lung Centre Charity

No information available

Results and Publications

Intention to publish date01/05/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request, Published as a supplement to the results publication
Publication and dissemination planIt is intended the results of the study will be published in a doctoral thesis, high-impact peer-reviewed journals and presented at conferences so that we can explain to the healthcare community what our research results have shown. Direct quotes from one-to-one conversations may be used in the publication of results but these will be anonymised. Following the end of the study a general newsletter will be available to all participants who took part in the study.
IPD sharing planThe datasets generated during and/or analysed during the current study will be available upon request from Jemma Haines (jemma.haines@mft.nhs.uk).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file version 1.3 19/01/2024 24/01/2024 No No

Additional files

44931_PROTOCOL_v1.3_19Jan24.pdf

Editorial Notes

25/10/2024: The following changes were made to the study record:
1. The recruitment end date was changed from 31/10/2024 to 31/12/2024.
2. The overall study end date was changed from 31/10/2024 to 31/12/2024.
08/03/2024: The ethics approval was added.
07/02/2024: Internal review.
24/01/2024: Study's existence confirmed by the HRA.